These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36148674)

  • 1. Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada.
    Kim S; Chuang ES; Sabaiduc S; Olsha R; Kaweski SE; Zelyas N; Gubbay JB; Jassem AN; Charest H; De Serres G; Dickinson JA; Skowronski DM
    Euro Surveill; 2022 Sep; 27(38):. PubMed ID: 36148674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23.
    Skowronski DM; Chuang ES; Sabaiduc S; Kaweski SE; Kim S; Dickinson JA; Olsha R; Gubbay JB; Zelyas N; Charest H; Bastien N; Jassem AN; De Serres G
    Euro Surveill; 2023 Feb; 28(5):. PubMed ID: 36729117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV).
    Skowronski DM; Sabaiduc S; Leir S; Rose C; Zou M; Murti M; Dickinson JA; Olsha R; Gubbay JB; Croxen MA; Charest H; Bastien N; Li Y; Jassem A; Krajden M; De Serres G
    Euro Surveill; 2019 Nov; 24(46):. PubMed ID: 31771709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN).
    Skowronski DM; Zhan Y; Kaweski SE; Sabaiduc S; Khalid A; Olsha R; Carazo S; Dickinson JA; Mather RG; Charest H; Jassem AN; Levade I; Hasso M; Zelyas N; Gao R; Bastien N
    Euro Surveill; 2024 Feb; 29(7):. PubMed ID: 38362622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016-2017 and 2017-2018 Epidemics in Canada.
    Skowronski DM; Leir S; Sabaiduc S; Chambers C; Zou M; Rose C; Olsha R; Dickinson JA; Winter AL; Jassem A; Gubbay JB; Drews SJ; Charest H; Chan T; Hickman R; Bastien N; Li Y; Krajden M; De Serres G
    J Infect Dis; 2022 Apr; 225(8):1387-1398. PubMed ID: 32215564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018-2019.
    Melidou A; Hungnes O; Pereyaslov D; Adlhoch C; Segaloff H; Robesyn E; Penttinen P; Olsen SJ;
    Vaccine; 2020 Jul; 38(35):5707-5717. PubMed ID: 32624252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza returns with a season dominated by clade 3C.2a1b.2a.2 A(H3N2) viruses, WHO European Region, 2021/22.
    Melidou A; Ködmön C; Nahapetyan K; Kraus A; Alm E; Adlhoch C; Mooks P; Dave N; Carvalho C; Meslé MM; Daniels R; Pebody R; ;
    Euro Surveill; 2022 Apr; 27(15):. PubMed ID: 35426364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Krajden M; Gubbay JB; Drews SJ; Martineau C; Eshaghi A; Kwindt TL; Bastien N; Li Y
    Clin Infect Dis; 2016 Jul; 63(1):21-32. PubMed ID: 27025838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021-2022 Influenza Season.
    Price AM; Flannery B; Talbot HK; Grijalva CG; Wernli KJ; Phillips CH; Monto AS; Martin ET; Belongia EA; McLean HQ; Gaglani M; Mutnal M; Geffel KM; Nowalk MP; Tartof SY; Florea A; McLean C; Kim SS; Patel MM; Chung JR
    Clin Infect Dis; 2023 Apr; 76(8):1358-1363. PubMed ID: 36504336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022.
    Tenforde MW; Patel MM; Lewis NM; Adams K; Gaglani M; Steingrub JS; Shapiro NI; Duggal A; Prekker ME; Peltan ID; Hager DN; Gong MN; Exline MC; Ginde AA; Mohr NM; Mallow C; Martin ET; Talbot HK; Gibbs KW; Kwon JH; Chappell JD; Halasa N; Lauring AS; Lindsell CJ; Swan SA; Hart KW; Womack KN; Baughman A; Grijalva CG; Self WH;
    Clin Infect Dis; 2023 Mar; 76(6):1030-1037. PubMed ID: 36327388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.
    Skowronski DM; Chambers C; Sabaiduc S; Dickinson JA; Winter AL; De Serres G; Drews SJ; Jassem A; Gubbay JB; Charest H; Balshaw R; Bastien N; Li Y; Krajden M
    Euro Surveill; 2017 Feb; 22(6):. PubMed ID: 28205503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-Emergence of Circulation of Seasonal Influenza during COVID-19 Pandemic in Russia and Receptor Specificity of New and Dominant Clade 3C.2a1b.2a.2 A(H3N2) Viruses in 2021-2022.
    Kolosova NP; Ilyicheva TN; Unguryan VV; Danilenko AV; Svyatchenko SV; Onhonova GS; Goncharova NI; Kosenko MN; Gudymo AS; Marchenko VY; Shvalov AN; Susloparov IM; Tregubchak TV; Gavrilova EV; Maksyutov RA; Ryzhikov AB
    Pathogens; 2022 Nov; 11(11):. PubMed ID: 36422639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Intense Influenza A(H1N1)pdm09 Epidemic and Vaccine Effectiveness in the Post-COVID Season in the Russian Federation.
    Sominina A; Danilenko D; Komissarov AB; Pisareva M; Fadeev A; Konovalova N; Eropkin M; Petrova P; Zheltukhina A; Musaeva T; Eder V; Ivanova A; Komissarova K; Stolyarov K; Karpova L; Smorodintseva E; Dorosh A; Krivitskaya V; Kuznetzova E; Majorova V; Petrova E; Boyarintseva A; Ksenafontov A; Shtro A; Nikolaeva J; Bakaev M; Burtseva E; Lioznov D
    Viruses; 2023 Aug; 15(8):. PubMed ID: 37632122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023.
    Lewis NM; Zhu Y; Peltan ID; Gaglani M; McNeal T; Ghamande S; Steingrub JS; Shapiro NI; Duggal A; Bender WS; Taghizadeh L; Brown SM; Hager DN; Gong MN; Mohamed A; Exline MC; Khan A; Wilson JG; Qadir N; Chang SY; Ginde AA; Mohr NM; Mallow C; Lauring AS; Johnson NJ; Gibbs KW; Kwon JH; Columbus C; Gottlieb RL; Raver C; Vaughn IA; Ramesh M; Johnson C; Lamerato L; Safdar B; Casey JD; Rice TW; Halasa N; Chappell JD; Grijalva CG; Talbot HK; Baughman A; Womack KN; Swan SA; Harker E; Price A; DeCuir J; Surie D; Ellington S; Self WH;
    Clin Infect Dis; 2024 Apr; 78(4):1056-1064. PubMed ID: 38051664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza Incidence and Vaccine Effectiveness During the Southern Hemisphere Influenza Season - Chile, 2022.
    Olivares Barraza MF; Fasce RA; Nogareda F; Marcenac P; Vergara Mallegas N; Bustos Alister P; Loayza S; Chard AN; Arriola CS; Couto P; García Calavaro C; Rodriguez A; Wentworth DE; Cuadrado C; Azziz-Baumgartner E
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(43):1353-1358. PubMed ID: 36301733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay J; Fonseca K; Charest H; Krajden M; Petric M; Mahmud SM; Van Caeseele P; Bastien N; Eshaghi A; Li Y
    J Infect Dis; 2015 Sep; 212(5):726-39. PubMed ID: 25784728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic and virological properties of an H3N2 variant that continues to dominate the 2021-22 Northern Hemisphere influenza season.
    Bolton MJ; Ort JT; McBride R; Swanson NJ; Wilson J; Awofolaju M; Furey C; Greenplate AR; Drapeau EM; Pekosz A; Paulson JC; Hensley SE
    Cell Rep; 2022 May; 39(9):110897. PubMed ID: 35649381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza vaccine effectiveness in preventing laboratory-confirmed influenza in outpatient settings: A test-negative case-control study in Beijing, China, 2016/17 season.
    Wu S; Pan Y; Zhang X; Zhang L; Duan W; Ma C; Zhang Y; Zhang M; Sun Y; Yang P; Wang Q; Ma J
    Vaccine; 2018 Sep; 36(38):5774-5780. PubMed ID: 30087046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018.
    Skowronski DM; Chambers C; De Serres G; Dickinson JA; Winter AL; Hickman R; Chan T; Jassem AN; Drews SJ; Charest H; Gubbay JB; Bastien N; Li Y; Krajden M
    Euro Surveill; 2018 Feb; 23(5):. PubMed ID: 29409570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The resurgence of influenza A/H3N2 virus in Australia after the relaxation of COVID-19 restrictions during the 2022 season.
    Wang X; Walker G; Kim KW; Stelzer-Braid S; Scotch M; Rawlinson WD
    J Med Virol; 2024 Sep; 96(9):e29922. PubMed ID: 39295292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.